Blossomhill Therapeutics (BLSM) closed at $14.63 on October 23, 2026, down 7.5% from the previous close, on volume of 83,843 shares (30-day average 208,859).
Data as of October 23, 2026.
TipRanks (Fri, 23-Oct 8:03 AM ET)
Globe Newswire (Thu, 22-Oct 7:00 AM ET)
Globe Newswire (Mon, 28-Sep 7:00 AM ET)
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Globe Newswire (Fri, 18-Sep 7:00 AM ET)
Globe Newswire (Tue, 15-Sep 7:00 AM ET)
Globe Newswire (Thu, 3-Sep 7:00 AM ET)
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Blossomhill Therapeutics trades on the NASDAQ stock market under the symbol BLSM.
As of October 23, 2026, BLSM stock price declined to $14.63 with 83,843 million shares trading.
BLSM has a market cap of $465.01 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that BLSM belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
BLSM support price is $14.73 and resistance is $16.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLSM shares will trade within this expected range on the day.
